Brief: Nicox Q3 Net Revenue At EUR 0.8 Million
20/10/2020 06:39
Oct 20 (Reuters) - Nicox SA NCOX.PA :
* Q3 NET REVENUE OF EUR 0.8 MILLION
* NICOX ANNOUNCES THIRD QUARTER 2020 BUSINESS UPDATE AND FINANCIAL
HIGHLIGHTS
* CASH OF EUR 42.2 MILLION AS OF SEPTEMBER 30, 2020
* VYZULTA (®)U.S. PRESCRIPTIONS IN Q3 2020 INCREASED BY 45% OVER Q3 2019
* ZERVIATE (TM)U.S. PRESCRIPTIONS IN Q3 2020 INCREASED BY 176% OVER Q2 2020,
FIRST
FULL QUARTER OF SALES
* ZERVIATE (TM)CHINA : A PHASE 3 CLINICAL TRIAL INTENDED TO SUPPORT AN
APPLICATION
FOR REGULATORY APPROVAL IN CHINA IS EXPECTED TO START BY END OF 2020
* NITRIC OXIDE (NO)-DONATING PHOSPHODIESTERASE-5 (PDE5) INHIBITORS FOR IOP
LOWERING: IND-TRACK CANDIDATE EXPECTED TO BE ANNOUNCED SHORTLY
* CONTINUES TO CLOSELY WATCH SPREAD AND IMPACT OF COVID-19 PANDEMIC
* ON COVID: DOES NOT CURRENTLY ANTICIPATE DELAYS IN CLINICAL TIMELINES BUT
MONITORES SITUATION AND WILL PROVIDE AN UPDATE WHEN NEEDED
* SELECTION OF 0.1% DOSE OF NCX 470 ENABLES SECOND PART OF MONT BLANC PHASE
3
TRIAL IN GLAUCOMA AND INITIATION OF SECOND PHASE 3 TRIAL, DENALI, EXPECTED BY
END 2020
Further company coverage: NCOX.PA
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))